Literature DB >> 7396448

Cefoxitin penetration into cerebrospinal fluid in patients with purulent meningitis.

P A Galvao, A V Lomar, W Francisco, C V de Godoy, R Norrby.   

Abstract

The penetration of cefoxitin into cerebrospinal fluid (CSF) was studied in 25 patients with purulent meningitis treated with antibiotics other than cefoxitin. Each patient received three 2-g doses of cefoxitin at 6-h intervals. Blood and CSF samples were obtained before and at 2, 4, or 6 h after the first and third doses. CSF cefoxitin concentrations were found in all patients and varied between 1.2 and 22.0 microgram/ml, with a majority of the concentrations falling within a range from 1.2 to 6.2 microgram/ml. The concentrations tended to be higher in CSF samples drawn after the third cefoxitin dose than in those drawn after the first cefoxitin dose, indicating an accumulation of cefoxitin in CSF with repeated doses. Peak cefoxitin concentrations in CSF seemed to occur between 2 and 6 h after intravenous administration of the drug since the highest concentrations were found in patients from whom CSF samples were taken 4 h after the doses. In patients with bacterial meningitis, it should be possible to achieve therapeutic cefoxitin levels in CSF by using nontoxic doses of the antibiotic.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7396448      PMCID: PMC283826          DOI: 10.1128/AAC.17.4.526

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  A review of the penetration of antibiotics into CSF and its clinical significance.

Authors:  R Norrby
Journal:  Scand J Infect Dis Suppl       Date:  1978

2.  Penetration of cefoxitin into cerebrospinal fluid of dogs with and without experimental meningitis.

Authors:  P Massip; M D Kitzis; V T Tran; M J Armengaud; M Armengaud
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

Review 3.  The penetration of antibiotics into cerebrospinal fluid and brain tissue.

Authors:  R W Barling; J B Selkon
Journal:  J Antimicrob Chemother       Date:  1978-05       Impact factor: 5.790

4.  Haemophilus influenzae type B resistant to ampicillin. A report of two cases.

Authors:  W Khan; S Ross; W Rodriguez; G Controni; A K Saz
Journal:  JAMA       Date:  1974-07-15       Impact factor: 56.272

5.  Letter: Ampicillin-resistant Haemophilus influenzae meningitis.

Authors:  W J Thomas; J W McReynolds; C R Mock; D W Bailey
Journal:  Lancet       Date:  1974-02-23       Impact factor: 79.321

6.  Penetration of cefoxitin into human cerebrospinal fluid: comparison with cefamandole, ampicillin, and penicillin.

Authors:  C Liu; D R Hinthorn; G R Hodges; J L Harms; G Couchonnal; D L Dworzack
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

7.  Penetration of cefoxitin into cerebrospinal fluid and treatment of meningitis caused by gram-negative bacteria.

Authors:  S R Nair; C E Cherubin; M Weinstein
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb

Review 8.  Cefoxitin and cephamycins: microbiological studies.

Authors:  E O Stapley; J Birnbaum; A K Miller; H Wallick; D Hendlin; H B Woodruff
Journal:  Rev Infect Dis       Date:  1979 Jan-Feb
  8 in total
  4 in total

Review 1.  Cephalosporins in the treatment of meningitis.

Authors:  H C Neu
Journal:  Drugs       Date:  1987       Impact factor: 9.546

2.  Penetration of cefoxitin into cerebrospinal fluid of infants and children with bacterial meningitis.

Authors:  W E Feldman; S Moffitt; N S Manning
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

3.  Cefotaxime in treatment of meningitis and ventriculitis? Evaluation of drug concentrations in human cerebrospinal fluid.

Authors:  O Brückner; H Collmann; H G Hoffmann
Journal:  Intensive Care Med       Date:  1982-01       Impact factor: 17.440

4.  Systematic Review of the Pharmacological Evidence for the Selection of Antimicrobials in Bacterial Infections of the Central Nervous System in Dogs and Cats.

Authors:  Robert Hertzsch; Angelika Richter
Journal:  Front Vet Sci       Date:  2022-01-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.